1801 Aktienübersicht Innovent Biologics, Inc. ist ein biopharmazeutisches Unternehmen, das monoklonale Antikörper und andere Arzneimittel in den Bereichen Onkologie, Augenheilkunde, Autoimmunerkrankungen sowie Herz-Kreislauf- und Stoffwechselkrankheiten in der Volksrepublik China entwickelt und vermarktet. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Innovent Biologics, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Innovent Biologics Historische Aktienkurse Aktueller Aktienkurs HK$35.20 52-Wochen-Hoch HK$52.15 52-Wochen-Tief HK$28.30 Beta 0.24 1 Monat Veränderung -8.57% 3 Monate Veränderung -17.37% 1 Jahr Veränderung -8.09% 3 Jahre Veränderung -28.74% 5 Jahre Veränderung n/a Veränderung seit IPO -38.35%
Aktuelle Nachrichten und Updates
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Co-Founder recently sold HK$81m worth of stock Oct 05
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26 Weitere Updates anzeigen
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Co-Founder recently sold HK$81m worth of stock Oct 05
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Aug 29
Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China Aug 22
The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert Aug 21
Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) Aug 02
the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc Aug 01
Forecast to breakeven in 2025 Jul 22
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions Jun 25
High number of new directors Jun 01
Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA May 29
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 May 23
Co-Founder recently sold HK$37m worth of stock May 12
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer May 08
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) May 01
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer Apr 30
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application Apr 02
Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024 Mar 21
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) Mar 21
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Mar 07
Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer Mar 06
Now 25% undervalued after recent price drop Mar 02
Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 01
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease Feb 20
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee Feb 10
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China Feb 07 Innovent Biologics, Inc. Announces Chief Financial Officer Changes Feb 05
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints Jan 09
China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib Dec 19
Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications Dec 18
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Dec 08
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351 Nov 25
Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib Nov 23
Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care Nov 22
The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients Nov 18
Now 20% undervalued Nov 03
Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity Oct 30
Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor) Sep 29
Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 21 Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 20
New minor risk - Shareholder dilution Sep 20
First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022) Aug 24
National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo Aug 17
Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Aug 08 IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting Jun 12 Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC Jun 05
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Jun 03
Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint May 11
Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy May 10
Full year 2022 earnings released: CN¥1.46 loss per share (vs CN¥2.16 loss in FY 2021) Mar 29
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Feb 16
Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy Feb 15
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications Jan 19
Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Jan 10
Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib Jan 06
Forecast to breakeven in 2025 Dec 31 Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Dec 05
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity Nov 15
Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022 Nov 07
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors Oct 31
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 19
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 17 Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.69 loss in 1H 2021) Oct 01
Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study Sep 08
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 07
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 06
No longer forecast to breakeven Aug 27
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.81 loss in 1H 2021) Aug 26
Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies Aug 24
Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) Aug 18
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint Aug 11
Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema Aug 08 Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V. Aug 05
Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy Aug 01 Aktionärsrenditen 1801 HK Biotechs HK Markt 7D -5.9% -3.9% -0.5% 1Y -8.1% -5.7% 19.9%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 1801 unter dem Niveau der Branche Hong Kong Biotechs , die im vergangenen Jahr eine Rendite von -5.7% erzielte.
Rendite vs. Markt: 1801 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 19.9 erzielte.
Preisvolatilität Is 1801's price volatile compared to industry and market? 1801 volatility 1801 Average Weekly Movement 8.5% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stabiler Aktienkurs: 1801 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: 1801Die wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Innovent Biologics, Inc. ist ein biopharmazeutisches Unternehmen, das monoklonale Antikörper und andere Arzneimittel in den Bereichen Onkologie, Augenheilkunde, Autoimmun-, Herz-Kreislauf- und Stoffwechselerkrankungen in der Volksrepublik China entwickelt und vermarktet. Das Unternehmen bietet Tyvyt, einen humanen monoklonalen Anti-PD-1-Antikörper, BYVASDA, einen vollständig humanen monoklonalen Anti-VEGF-Antikörper, HALPRYZA, einen rekombinanten chimären monoklonalen Anti-CD20-Antikörper aus Maus und Mensch; SULINNO, ein vollständig humaner monoklonaler Anti-TNF-a-Antikörper; Pemazyre, ein selektiver FGFR-Inhibitor; Olverembatinib, ein neuartiger BCR-ABL-TK; Cyramza, ein VEGF-Rezeptor-2-Antagonist; und Retsevmo, ein selektiver und potenter RET-Kinase-Inhibitor. Das Unternehmen entwickelt außerdem IBI-326, eine vollständig humane BCMA-CAR-T-Zelltherapie; IBI-376, einen oralen Inhibitor von PI3Kd; IBI-351, einen KRASG12C-Inhibitor; IBI-344, einen Repressor von Silencing 1/TRK-Tyrosinkinase-Inhibitor; IBI-126, ein ADC, das auf CEACAM5 abzielt; IBI-306, ein neuartiger monoklonaler Antikörper gegen das Enzym Protein-Convertase-Subtilisin/Kexin Typ 9; IBI-362, ein dualer Agonist des Glucagon-ähnlichen Peptid-1-Rezeptors/Glucagon-Rezeptors; und IBI-112, ein neuartiges lang wirkendes Anti-IL-23.
Mehr anzeigen Innovent Biologics, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Innovent Biologics im Vergleich zum Marktanteil des Unternehmens? 1801 grundlegende Statistiken Marktanteil HK$57.65b Gewinn(TTM ) -HK$1.37b Umsatz(TTM ) HK$7.95b
7.3x Kurs-Umsatz-Verhältnis
-42.2x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 1801 Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥7.46b Kosten der Einnahmen CN¥2.12b Bruttogewinn CN¥5.34b Sonstige Ausgaben CN¥6.62b Umsatz -CN¥1.28b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -0.78 Bruttomarge 71.58% Nettogewinnspanne -17.18% Schulden/Eigenkapital-Verhältnis 25.8%
Wie hat sich 1801 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2024/12/21 16:55 Aktienkurs zum Tagesende 2024/12/20 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen Innovent Biologics, Inc. wird von 53 Analysten beobachtet. 29 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Bo Li BofA Global Research
50 weitere Analysten anzeigen 
